Methods: BioThreat-E test was evaluated on urine and saliva specimens, in comparison with routine blood testing [QuantiTect Probe RT-PCR® (Qiagen) confirmed by RealStar® Filovirus Type RT-PCR Kit 1.0 (Altona)] in EVD-suspected cases in a diagnostic and treatment center in Guinea. Urine and saliva were requested for all patients enrolled in the study, but analysis was performed on EV positive patients only.
Results: As of May 8, 2015 after 2 months of enrollment, 78 EVD-suspected patients were enrolled, with 35 positive by routine testing. Of the 35 positives, 18 patients gave a saliva sample and 7 gave a urine sample. In all 25 non-blood samples, the BioThreat-E test was positive, demonstrating 100% sensitivity for these 2 specimen types in this select patient population. The study is still ongoing.
Conclusion: In field conditions in Guinea, the FA BioThreat-E test has a very high sensitivity for diagnosing EVD from urine and saliva. This test requires no sample prep, is easy to use, and gives results in about 1 hour. The BioThreat-E test, when performed on non-invasive samples like saliva and urine could be an immensely helpful tool for the individual diagnosis as well as surveillance of Ebola Virus in many different settings, including “in the field” in low-resource settings as well as in any category of laboratory.
V. Picot, None
C. Peyrefitte, None
B. Dacosta, bioMérieux: Employee , Salary
F. Bedin, bioMerieux: Employee , Salary
A. Doré, None
F. Kourouma, None
J. L. Machuron, None
C. Longuet, None
C. Phillips, BioFire Defense: Employee , Salary
M. Scullion, BioFire Defense: Employee , Salary
M. Miller, bioMerieux: Employee , Salary